Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprotirome SCHEMBL29357083 | 0.82 | THRA (1.00) | THRBTHRA | |
| Eprotirome SCHEMBL759034 | 0.82 | THRA (1.00) | THRBTHRA | |
| SCHEMBL4559561 | 0.80 | THRA (0.76) | THRBTHRA | |
| SCHEMBL3137511 | 0.77 | THRA (0.52) | THRBTHRA | |
| SCHEMBL14451793 | 0.77 | THRB (0.57) | THRBTHRA | |
| SCHEMBL8230418 | 0.76 | THRA (0.88) | THRBTHRA | |
| SCHEMBL7533399 | 0.76 | THRA (0.65) | THRBTHRA | |
| SCHEMBL2041087 | 0.73 | THRA (0.84) | THRBTHRA | |
| SCHEMBL3146203 | 0.73 | THRA (0.58) | THRBTHRA | |
| SCHEMBL19498640 | 0.73 | THRA (0.83) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| EP-3955954-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM Biopharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2020214753-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM BIOPHARMACEUTICALS, INC. (US) | 2020-10-22 | — | — | WO | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-3955954-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM Biopharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-113286608-A | Chimeric Antigen Receptor (CAR) groups | 圣安娜儿童癌症研究中心 | 2021-08-20 | — | — | CN | disclosed |
| WO-2020214753-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM BIOPHARMACEUTICALS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2014023698-A1 | EPROTIROME FOR USE IN THE PREVENTION AND/OR TREATMENT OF HAIR DISORDERS AND COMPOSITIONS THEREOF | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTTEL (DE) | 2014-02-13 | — | — | WO | disclosed |
| EP-2231121-A2 | PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077147-A2 | PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2004168-A1 | STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING THYROID HORMONE RECEPTOR AGONISTS | KARO BIO AB (SE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007110226-A1 | STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING THYROID HORMONE RECEPTOR AGONISTS | KARO BIO AB (SE) | 2007-10-04 | — | — | WO | disclosed |